DPHARMA 7148

DPHARMA 7148 Share Price

RM2.86

(13 customer reviews)
52 Weeks Range : 2.35 - 4.38

5 day volume Average = 1,970,560
20 day volume Average = 1,444,280
90 day volume Average = 2,865,577
Add to wishlistAdded to wishlistRemoved from wishlist 4
Add to compare
4.7/10 (Expert Score)
Product is rated as #1 in category Biotechnology
Prospective Profit
3.515
Assets
2.257
Dividend/ Cash
4.975
Liquidity
7.968
PROS:
  • Small Dividend Payout
  • Very High Trading Value
CONS:
  • Very Low Price-to-Tangible

klse: Duopharma Biotech Bhd


Corporate Information

Board   : Main

Shariah : Shariah Compliant

Sector   : Biotechnology Ringgit Consumer Healthcare

Address: Suite 18.06, Level 18, Kenanga International, No. 26, Jalan Sultan Ismail, 50250, Kuala Lumpur

Contact: +603-21620218

Website: https://www.duopharmabiotech.com/
 

Corporate Background

Duopharma Biotech Berhad operates as an investment holding company. The Company, through its subsidiaries, invests in the pharmaceutical and healthcare sectors. Duopharma Biotech serves customers in Malaysia.

Genaral Info: DPHARMA 7148

Market Capital (RM) 309, 074, 185
Forecasted Profit or Loss (RM) 11, 102, 088
Estimated Future EPS (sen) 2.281
Perspective P/E ratio 27.839
Estimated Dividend Yield (%) 1.228
Adjusted NTA (RM) 0.16

Result

Quarter Report History

Date Revenue,k PBT,k Net Profit,k
03/05/21 166,454 23,176 17,614
22/02/21 134,086 20,471 16,193
12/11/20 133,772 18,568 14,127
13/08/20 143,331 19,391 14,729
18/05/20 158,713 17,727 13,561
13/02/20 137,755 13,939 12,033
29/11/19 142,855 19,768 14,859
30/08/19 145,466 18,316 13,916
21/05/19 150,386 18,786 14,465
18/02/19 115,634 17,658 14,369
28/11/18 125,838 15,838 12,286
26/11/18 123,991 12,915 10,339

Fundamental

Fundamental Analysis

Last 4 Quarter Revenue (RM’000) 577,643
Last 4 Quarter Net Profit (RM’000) 62,663
Last 4 Quarter EPS (sen) 8.96
Last 4 Quarter PER 32.24
Last 4 Quarter Dividend (sen) 6.50
Last 4 Quarter Dividend Yield (%) 2.27
Net Tangible Assets (RM) 0.91
Goodwill (RM) 35,070
Cash (RM’000) 158,030
Debt (RM’000) 302,730
Total Debt (RM’000) 430,050
Net Assets (RM’000) 643,820
Current Ratio 3.06
Quick Ratio 2.05
Cash Ratio 1.05

Technical

Technical Analysis

MACD (26 vs 12) -0.034
Exponential Moving Average 5 2.924
Exponential Moving Average 20 2.965
Exponential Moving Average 90 3.009
Relative Strength Index 14 0.42
Stochastic %D 3 0.41
Stochastic %K 14 0.36

13 reviews for DPHARMA 7148

3.1 out of 5
0
3
4
2
0
Write a review
Show all Most Helpful Highest Rating Lowest Rating
  1. Avatar

    The Edge

    Duopharma Biotech Bhd said today it has signed an agreement with the government to supply 6.4 million doses of the Sputnik V vaccine to Malaysia. Through its wholly-owned subsidiary Duopharma (M) Sdn Bhd, it concluded the execution of separate definitive supply agreements with the Malaysian government (represented by the Ministry of Health) and a subsidiary of the Russian Direct Investment Fund for the supply.

    Helpful(0) Unhelpful(0)You have already voted this
  2. Avatar

    The Star

    Shares of Pharmaniga Bhd and Duopharma Biotech Bhd climbed in active trade on Wednesday as the companies sign agreement with the Government to supply Covid-19 vaccine. Duopharma added six sen to RM3.76. Duopharma said it would supply 6.4 million doses of Sputnik V developed by Russia’s Gamaleya Research Institute to the government.

    Helpful(0) Unhelpful(0)You have already voted this
  3. Avatar

    The Edge

    AmInvestment Bank Bhd (AmInvest) believes that Pharmaniaga Bhd would be the main distributor of the Covid-19 vaccine to local hospitals, and may appoint other companies to help distribute the vaccine nationwide. In terms of fill-finish companies, AmInvest said while a deal concerning Covid-19 vaccine’s fill-finish process has yet to materialise, the government seems to favour Duopharma Biotech Bhd and Pharmaniaga to undertake these processes.

    Helpful(0) Unhelpful(0)You have already voted this
  4. Avatar

    The Edge

    Duopharma Biotech Bhd said the government has extended the agreement for the supply and delivery of human insulin products by one year from Dec 2, 2020 to Dec 1, 2021, with an additional contract value of RM19.625 million. Following this second additional contract, the total contract value has been increased to RM410.725 million from RM300.04 million under the original agreement.

    Helpful(0) Unhelpful(0)You have already voted this
  5. Avatar

    The Edge

    Duopharma Biotech Bhd’s third-quarter (3Q) net profit fell 4.93% to RM14.13 million, from RM14.86 million a year earlier, due to a drop in revenue on lower demand from the private ethical sector. Even with the ongoing scenario comprising global and domestic upheavals largely attributed to the Covid-19 pandemic, these solid financial results attest to higher demand for the group’s pharmaceutical products especially from the consumer healthcare sector

    Helpful(0) Unhelpful(0)You have already voted this
  6. Avatar

    BURSA MALAYSIA

    The Group has recorded a lower revenue of RM 133.77 million for the current quarter ended 30 September 2020 as compared to RM 143.33 million for the preceding financial quarter. Decrease in Group’s revenue was mainly due to lower demand from private healthcare sector due to challenging environment faced by private clinics and hospitals. The Group’s PBT decreased by 4.24% to RM 18.57 million in the current quarter as compared to RM 19.39 million in the preceding financial quarter, mainly due to lower revenue in the current quarter

    Helpful(0) Unhelpful(0)You have already voted this
  7. Avatar

    The Star

    The efficacy of a potential Covid-19 vaccine continues to be a concern even as the need for it becomes prevalent. This has allowed glove stocks to sustain their gains, while pharmaceutical counters are also seeing some gains, but not yet a strong interest moving into their shares. Locally based pharmaceutical stocks have seen some gains following a probable vaccine development by the end of the year and into 2021. Pharmaniaga Bhd rose 20 sen to close at RM5.39 last Friday, while Duopharma Biotech Bhd rose 18 sen to RM3.94.

    Helpful(0) Unhelpful(0)You have already voted this
  8. Avatar

    The Edge

    Duopharma Biotech stock price has seen a steady rise since July amid vaccine optimism and it is expected to continue its upward momentum as the Employees Provident Fund (EPF) has increased its holdings. In terms of stake, Duopharma’s majority shareholder Bumiputera Investment Foundation holds 46.5 per cent, EPF (7.82 per cent) and Permodalan Nasional Bhd (4.94 per cent).

    Helpful(0) Unhelpful(0)You have already voted this
  9. Avatar

    BURSA MALAYSIA

    The Group has recorded a lower revenue of RM 143.33 million for the current quarter ended 30 June 2020 as compared to RM 158.71 million for the preceding financial quarter. Decrease in Group’s revenue was mainly due to lower demand from public health sector and also challenging environment faced by private clinics and hospitals during the Movement Control Order (MCO). However, the Group’s PBT increased by 9.39% to RM 19.39 million in the current quarter as compared to RM 17.73 million in the preceding financial quarter, mainly due to strengthening of US Dollar resulting in unrealised forex losses on our borrowings in USD in our loan portfolio in the preceding financial quarter.

    Helpful(0) Unhelpful(0)You have already voted this
  10. Avatar

    BURSA MALAYSIA

    The Group has recorded a higher revenue and PBT of RM158.71 million and RM17.73 million for the current quarter ended 31 March 2020 as compared to RM 137.76 million and RM 13.94 million respectively for the preceding quarter. Increase in Group’s revenue was mainly due to trending lower sales in public health sector towards year end. Increase in revenue and better GP Margin led to higher PBT from RM 13.94 million to RM 17.73 million.

    Helpful(0) Unhelpful(0)You have already voted this
  11. Avatar

    REMUNERATION STUDY

    In Financial Year End 2019, the directors’ remuneration was 2.86 million. It was fair compared to average in listed companies, considering the employees’ remuneration of 115 million and auditor’s remuneration of 250 thousands

    Helpful(0) Unhelpful(0)You have already voted this
  12. Avatar

    BURSA MALAYSIA

    The Group has recorded a lower revenue and PBT of RM 137.76 million and RM 13.94 million for the current quarter ended 31 December 2019 as compared to RM 142.86 million and RM 19.77 million respectively for the preceding quarter. Decrease in Group’s revenue was mainly due to trending lower sales towards year end in public health sector. Decrease in revenue and higher operational costs have reduced PBT from RM 19.77mil to RM 13.94mil.

    Helpful(0) Unhelpful(0)You have already voted this
  13. Avatar

    INVESTING MALAYSIA

    DPHARMA (18 DEC 19) Duopharma Biotech Bhd continues to have a bullish outlook for its group performance next year, leveraging the country’s higher healthcare allocation under the 2020 Budget.

    Helpful(0) Unhelpful(0)You have already voted this
  14. Avatar

    Investing Malaysia

    Average investing volume for Duopharma Biotech Bhd in the past three months in stock market was 828.9k lots

    Helpful(0) Unhelpful(0)You have already voted this
  15. Avatar

    Investing Malaysia

    DPHARMA gets a score of 12.34 in our equity and assets quality test based on current share price of RM1.63

    Helpful(0) Unhelpful(0)You have already voted this
  16. Avatar

    Investing Malaysia

    Duopharma Biotech Bhd gets a score of 22.21 in our stability test after the balance sheet, money statement study

    Helpful(0) Unhelpful(1)You have already voted this
  17. Avatar

    Investing Malaysia

    Stock code of 7148 in Bursa Malaysia declared adjusted 3.54% dividend yield in past few years

    Helpful(0) Unhelpful(0)You have already voted this
  18. Avatar

    Investing Malaysia

    DPHARMA is estimated to have a profit consensus of 64.25 millions, with an adjusted market capitalization of 1088.17 millions

    Helpful(0) Unhelpful(0)You have already voted this
  19. Avatar

    REMUNERATION STUDY

    In Financial Year End 2018, the directors’ remuneration was 2.04 million. It was slightly low compared to average in listed companies, considering the employees’ remuneration of 94.9 million and auditor’s remuneration of 222 thousands

    Helpful(0) Unhelpful(0)You have already voted this

    Add a review

    Your email address will not be published.

    klse investing
    Register New Account
    Name (required)
    Reset Password
    Compare items
    • Total (0)
    Compare